How Pharmacists Can Stay at the Forefront of Patient Care in an Evolving Market

How Pharmacists Can Stay at the Forefront of Patient Care in an Evolving Market

Source: pharmacytimes.com

July 25, 2018 | By: Rebecca W. Chater, RPh, MPH, FAPhA

Amazon recently announced its entry into pharmacy through the acquisition of PillPack, a service that delivers medications, presorted in adherence packaging, to a patient’s home. The announcement has the pharmacy profession and the pharmaceutical industry debating several questions around the deal’s impact on local pharmacies and the role of the pharmacist in this process. At last estimate, the burden of nonadherence on our healthcare system exceeded $300 billion in direct and indirect costs, with approximately 50% of patients not taking their medications as prescribed, indicating a clear opportunity to mitigate related barriers to improved adherence.

While convenient access to medications certainly aids adherence, and could be facilitated by the PillPack acquisition, the deal stands to disrupt direct pharmacist-to-patient contact and the essential role of the community-based pharmacist within the healthcare continuum. Convenience of medication delivery is not a panacea for resolution of nonadherence and falls woefully short in addressing other critical aspects of addressing medication-related problems including unanticipated medication interactions, gaps in care, cost challenges, lack of patient education, lifestyle incompatibilities, and others.

Rather than focusing on the PillPack acquisition by Amazon as a threat, pharmacists should consider this as an opportunity to reassess the value that they bring—the existing patient care services, tools, and technology that equip them to deliver patient-centric, personalized care. Whether employing data analytics to more efficiently identify needed interventions, adherence packaging, or medication therapy management, pharmacies can enhance their service offerings to differentiate their practices and keep patients at the center of care.

Leveraging Adherence Tools

Pharmacists have long differentiated themselves with patients by stepping up to help with the confusion around managing multiple medications, and monitoring health issues. By using technology to streamline patient communications, and offering adherence tools, such as multimed blister cards, that can be customized to each patient, pharmacists can ensure they are not edged out by the online retailer.

This is especially true when patients experience care transitions. From one care setting to the next, they need the pharmacist as a local resource to help ensure smooth transition, and guide them on their path to better health outcomes. Research has shown that pharmacists are specially qualified to fulfill this role, helping to address concerns, and reduce medication errors that might not always be evident. The one-size-fits-all approach that Amazon is developing circumvents the role of the local pharmacist, and is not designed to meet the individualized needs of patients with unique health concerns.

Enhancing Pharmacy Care for Better Results

As our nation’s most accessible healthcare professionals, pharmacists serve as touchstones of care in communities all across the country, offering patient-centered, personalized, and coordinated care. Emerging data-driven solutions provide pharmacists with tools they need to increase their value through targeted clinical engagement, enabling them to further improve health outcomes, reduce healthcare costs, while offering a level of patient convenience that rivals Amazon-PillPack.

Centralized, actionable data specific to managing patient engagement is essential to improving care while reducing costs across the care continuum. For this reason, healthcare needs a system that not only provides convenience related to medication access—as this Amazon acquisition aims to do—but also keeps the pharmacist regularly connected to the patient to evaluate medication-related health needs on an ongoing basis, communicating as needed with patient and prescriber regarding medication adherence, potential medication changes or dosage adjustments, side effects, drug interactions, needed vaccinations, and more.

The coming months will reveal changes that result from the Amazon-PillPack deal. In the meantime, pharmacists should take this as an opportunity to amplify their value to further differentiate their practices, ensuring that their role will not be diminished by this new venture. By staying connected to their patients and implementing tools that help to expand their service offerings and improve patient care, today’s pharmacists will reinforce their own essential role in the care continuum, now and in the future.

PBM Transparency: PBM’s made $223 Million from Ohio Medicaid

PBMs made $223.7M from Ohio Medicaid in 2017

Source: daytondailynews.com

July 12, 2018 | BY Kaitlin Schroeder

For the first time, the state of Ohio on Friday released data showing how private companies manage $2.5 billion in public money for pharmacy benefits for Ohioans on Medicaid.

The middlemen, called pharmacy benefits managers, are under scrutiny for how transparent they are in how the public money gets spent. The new report shows the companies retained $223.7 million last year of the money they billed Medicaid.

Operators of small pharmacies have contended that the benefits managers take too much of the money and give pharmacists reimbursements that are too small. Some in the industry claim the low payments have forced small pharmacies out of business.

CVS Caremark, with the same parent company as CVS retail pharmacies, manages pharmacy benefits for four of the five Medicaid managed care companies. Last year it kept 8.7 percent or the payments it received, or $197.3 million. OptumRx does work for the other insurer and kept 9.4 percent, or $26.4 million.

Greg Moody, the director of the Ohio Department of Health Transformation, which oversees Ohio Medicaid, said Ohio needs more information before it determines what is a fair share for the pharmacy benefit managers.

“At this stage we’re not saying that’s too high or too low,” Moody said. “What we’re saying is this is information we’ve never had before. And now the state, the managed care plans, the pharmacies have more information to make their argument and determine if that number is too high or too low or what should happen next.”

The report shows the system saves the state money, Moody said. Medicaid saved $145 million under the privatized system compared to the former system where the state insurance program for the poor directly paid fees for services.

Ohio Association of Health Plans, which lobbies on behalf of the Medicaid managed care companies, said the new report confirms that the current system saves the state money. Attention should instead be focused on the pharmaceutical companies and their prices, according to Miranda C. Motter, president and CEO of Ohio Association of Health Plans.

“Further, this report proves that independent pharmacies are not underpaid and confirms that the real problem is the prices drug companies charge for prescriptions drugs are kept secret and that pricing is unsustainable for Ohio’s purchasers of health care,” Motter stated.

In 2017, the Dayton Daily News reported more than 90 pharmacies in Ohio closed their doors and others at the time said they may have to do the same because of a dramatic decrease in reimbursements from Medicaid managed care plans.

Since CVS Caremark also has the same parent company as CVS retail pharmacies, independent pharmacists have claimed their lowered reimbursements are an attempt to drive them out of business and give more Medicaid business to CVS. CVS has more than 9,000 locations nationwide.

From the state’s standpoint, Moody said his department wants its Medicaid enrollees to have access to the benefits they need and that they are getting a good price for tax payers.

Since their enrollees could access pharmacy services and the state was saving money, Moody said there wasn’t an initial need to have the type of data released in the report. The impetus for the report was to get enough information on whether these middlemen were engaging in fair business practices.

“From the state’s stand point there was no reason to ask this question except — and this is important — we don’t want to get a deal if it is at the price of anti-competitive behavior somewhere in the system,” he said.

The state had a third party, HealthPlan Data Solutions, create the report on prescription benefit data following recent criticism of pharmacy benefit managers. The report used claims data provided by the Medicaid managed care companies and matched it to Ohio Medicaid data.

Pharmacy benefit managers
New data shows the difference between what pharmacy benefit managers (PBMs) billed to Medicaid plans verses what they paid to pharmacies.
Managed Care Plan Price PBM Paid to Pharmacies Price PBM billed to Medicaid managed care plan Money PBM kept Percent PBM kept
Buckeye $268,014,861 $300,953,989 $32,939,128 10.94%
Caresource $1,289,174,707 $1,403,459,575 $114,284,868 8.14%
Molina $286,966,691 $313,813,700 $2,033,837 8.70%
Paramount $228,400,715 $250,914,832 $1,494,203 9.14%
UnitedHealthcare $253,372,283 $277,516,774 $2,765,797 9.41%
Source: HealthPlan Data Solutions   

From July 1, the state will be able to do the analysis themselves because of how it changed its contract with the Medicaid managed care companies.

CVS said in a statement that report’s finding show that CVS Caremark pays independent pharmacies a higher rate than CVS pharmacies — 3.6 more for brand prescriptions and 3.4 more for generics.

The company said this confirms it “does not provide preferential pricing to CVS Pharmacy that would create an anti-competitive advantage over independent pharmacies.”

CVS said some of the the money it keeps also pays for clinical services and other benefit management services provided to clients.

But Antonio Ciaccia, lobbyist with the Ohio Pharmacists Association, said “paying $224 million to essentially process claims is frankly remarkable.”

He said the report doesn’t disprove concerns that the middlemen companies are squeezing pharmacists. The data also doesn’t dig into whether the middlemen are paying too little given the cost of the drugs or pocketing too much for their services.

“What’s reasonable? It’s very hard to tell because we don’t have a competitive and transparent marketplace,” he said.

Moody said the pharmacy benefit manager debate is part of a broader issue that starts with frustration over how drug makers aren’t transparent on drug costs.

“Manufacturers go out of their way to keep prices secret and then everything that happens after that is in a sense distorted. Because I think everyone assumes someone else is getting a better deal and there’s a lot of distrust in the system,” he said.

Albertsons giving access to free education about genetic testing

Are you familiar with Pharmacogenetics aka genetic testing? By now, you should be… If you’re not, now is the time to start looking into it! A Trxade Member is generating an additional $1,000 per day doing genetic testing for their patients by doing a simple swab of their mouth and reviewing the results with their patients. It is customized, personalized healthcare and the future of effectively treating patients based on what is the most effective for them, not for the majority, for their specific DNA. It’s amazing! Jump on the ship before all of the big box chains start doing it, one has already started!

Albertsons has entered into a partnership with Genomind to give customers at nearly 30 in-store pharmacies access to free education about genetic testing intended to optimize medical treatment for mental health issues.

“Up to 50% of all mental health patients respond poorly to the first psychiatric medicine because everyone’s body is different, in part based on their individual genetic makeup.”

The test identifies patient-specific genetic markers that indicate which medications are likely to work as intended, have no effect or cause adverse effects.

At the select locations, specially trained pharmacists may decide to counsel a patient if they see a pattern of the patient having unsuccessful experiences with a medicine prescribed for any mental illness.

“We are excited to bring this opportunity to educate our patients about how genetic testing may be able to help them get better faster as they face mental health challenges,” says Albertsons Companies Senior Vice President of Pharmacy, Health & Wellness, Mark Panzer.

The pharmacist would be able to administer the test by collecting a small amount of saliva with a cheek swab in a private area of the pharmacy, and then review results of the genetic test with the patient after the test returns from Genomind’s CLIA-certified lab.

Genecept Assay platform covers more than 20 drug classes, 122 FDA-approved medications, 18 clinically validated genes and 97% of medications used to treat depression, anxiety, bipolar disorder, schizophrenia, attention-deficit disorder and autism, as well as comprehensive coverage of pain medications. It has shown in published studies to improve patient outcomes and reduce overall medical costs.

At Trxade’s 2018 annual conference we will have a CE on Pharmacogenetics taught by President-elect of the Florida Pharmacy Association David P. Mackarey, RPh., AAHIVP.

Topic: Pharmacogenetics, PGx: Taking It Personally

Learning Objectives:

  1. Understand PGx & It’s Relationship to Medication Therapy
  2. Create A Practical Application to Your Pharmacy
  3. Use A Collaborative Practice Agreement with Physicians to Implement A Successful Program
  4. Help Physicians Implement & Educate Patients on PGx
  5. Help Patients Understand Pharmacogenetics
  6. Educate Patients on The Importance of PGx
  7. Know the Step-By-Step Process of PGx Test
  8. Administer the PGx Test
  9. Explain the Meaning of The Results to The Patient
  10. Help Physicians Avoid Improper Drug/Dose Choices
  11. Use Lab Results to Achieve Best Possible Patient Outcomes

For additional information on the Trxade conference visit www.trxadeconference.com.

Sources: Supermarket News, PR News Wire